The FDA has told the company LabCorp there doesn't appear to be enough clinical data to prove the test actually works.
LabCorp and the FDA are in discussions on the issue, but the test, which costs about $230, is still being offered.
Ovarian cancer needs to be detected early to prevent spreading and increase its treatability. A new blood test designed to perform such early-stage detection is drawing criticism from the U.S. Food and Drug Administration. The diagnostic test Ovasure has been offered since June. Now the FDA says it hasn't been sufficiently tested and could lead to unnecessary operations based on false positives.